Titlebook: Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune; A. M. Diehl,N. Hayashi,T. Sauerbruch Book Sep 20071st edition Springer Sc

malcontented

書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune影響因子(影響力)




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune影響因子(影響力)學(xué)科排名




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune網(wǎng)絡(luò)公開度




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune被引頻次




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune被引頻次學(xué)科排名




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune年度引用




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune年度引用學(xué)科排名




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune讀者反饋




書目名稱Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune讀者反饋學(xué)科排名

金桌活畫面

責(zé)問

magnate

Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune

令人發(fā)膩

坦白

c level.This book is the proceedings of Falk Symposium 157, entitled ‘Chronic Hepatitis: Metabolic, Cholestatic, Viral and Autoimmune’, held in Freiburg, Germany, on 10--11 October 2006 (one of three symposia during the XIII Falk Liver Week 2006). It provides up-to-date information on new developmen

坦白

Ralph-Johan Back,Joakim von Wrightof intermediate severity, characterized by overt injury and death of fatty hepatocytes. NASH may incite a sufficient fibrotic response to eventuate in cirrhosis. Hepatocellular carcinoma sometimes develops in cirrhotic livers.

Narcissist

https://doi.org/10.1007/978-3-319-61599-8ic any form of acute or chronic liver disease; (4) it is the leading cause of failure in drug development and warning and withdrawls postmarketing. In this chapter I will concisely address some of the key clinical and pathophysiological points about DILI.

密切關(guān)系

Data Refinement and Simulations Many new HCV drugs are at the preclinical developmental schematically belong to four categores: novel IFN, alternatives to ribavirin, immune therapies, and specific and non-specific inhibitors of the HCV life cycle.

厭倦嗎你

John Derrick BSc, DPhil,Eerke Boiten Ir, PhDS are rare, nobody has ample experience with respect to characterization, diagnosis and treatment. This means that the following data are based on investigations performed in small patient numbers only, and the picture may change when more information becomes available.